Show Summary Details
Page of

Drug Treatment in Women 

Drug Treatment in Women
Drug Treatment in Women

Katherine T. Murray

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 31 July 2021

In the quest for a personalized approach to modern drug therapy, there is increasing evidence that sex matters. In cardiovascular therapeutics, sex-based considerations are particularly important with the use of antiarrhythmic drugs. In general, women have a greater incidence of adverse outcomes, especially drug-mediated proarrhythmia. Despite numerous studies, the mechanisms responsible for these sex-related differences are not fully understood. For optimal patient safety, practitioners must be aware of sex-based differences in outcomes related to antiarrhythmic drug therapy. This chapter reviews the evidence for the disparate responses between men and women to electrophysiologically active agents and highlights potential drug interactions of unique clinical significance for women.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.